Royalty Pharma Plc Stock Price, News & Analysis

Royalty Pharma plc (Nasdaq: RPRX) will participate in the Evercore ISI 4th Annual HealthCONx Virtual Conference on December 2, 2021, at 9:40 a.m. ET. The event will include a fireside chat accessible via the company’s Events page, with the webcast archived for at least thirty days. Founded in 1996, Royalty Pharma is a leader in funding biopharmaceutical innovation, holding royalties on approximately 40 commercial products from major pharmaceutical companies, facilitating advancements in healthcare.

On November 22, 2021, Royalty Pharma (RPRX) and OMERS Capital Markets announced $350 million funding for BioCryst Pharmaceuticals (BCRX). This capital will support the advancement of BCX9930, an oral Factor D inhibitor, and further investment in the global launch of ORLADEYO^® (berotralstat), which targets hereditary angioedema (HAE). Royalty Pharma's agreement includes royalties on sales and a $50 million equity investment in BioCryst at $13.00 per share. The funds will accelerate pivotal trials and regulatory filings for BCX9930, reinforcing BioCryst's growth strategy.

Royalty Pharma (RPRX) reported strong Q3 2021 results, with net cash from operating activities at $470 million and adjusted cash receipts rising 24% to $587 million. The company announced $2.8 billion in transactions for 2021, comprising $2.1 billion in upfront payments. Q3 2021 total income increased 9% to $586 million. The company raised its 2021 guidance for adjusted cash receipts to between $2,110 million and $2,130 million, representing 17%-18% growth year-on-year. Notable developments include positive Phase 3 results for PT027 in asthma and FDA designation of gantenerumab as a Breakthrough Therapy for Alzheimer’s.

Royalty Pharma (RPRX) will release its Q3 2021 financial results on November 10, 2021, before U.S. markets open. The announcement includes a conference call at 8:00 a.m. ET, accessible via phone and webcast. Royalty Pharma, a leader in biopharmaceutical royalties, partners with innovators to fund clinical trials and acquire royalties from top therapies, including Imbruvica and Xtandi. The company has royalties on over 45 commercial products and nine developmental candidates, positioning it as a significant player in the biopharmaceutical sector.

The board of directors of Royalty Pharma (RPRX) has approved a fourth-quarter 2021 dividend of $0.17 per Class A ordinary share. This dividend will be paid on December 15, 2021, to shareholders of record as of November 19, 2021. Royalty Pharma is the largest buyer of biopharmaceutical royalties, funding innovation through partnerships with various biotechnology and pharmaceutical companies. Their portfolio includes royalties from over 45 commercial products, enhancing their financial stability and attractiveness to investors.

Royalty Pharma plc (Nasdaq: RPRX) announced its participation in two investor conferences in September 2021. The events include Citi’s 16th Annual BioPharma Virtual Conference on September 9 at 10:40 a.m. EDT and Morgan Stanley’s 19th Annual Global Healthcare Conference on September 14 at 11:00 a.m. EDT. Webcasts will be available on Royalty Pharma’s 'Events' page and archived for at least 30 days. Royalty Pharma is known for acquiring biopharmaceutical royalties and funding innovation in the industry, with royalties on over 45 commercial products.

Royalty Pharma reported a strong second quarter for 2021, achieving a 9% increase in net cash provided by operating activities to $532 million, and a 3% rise in Adjusted Cash Receipts to $475 million. The company has raised its full-year 2021 guidance for Adjusted Cash Receipts to between $2,080 and $2,120 million, reflecting solid revenue growth driven by its cystic fibrosis franchise and new royalty acquisitions. Notably, Royalty Pharma completed up to $2.8 billion in announced transactions in 2021, solidifying its position in the biopharma royalty market.

Royalty Pharma plc (RPRX) is set to report its second quarter financial results on August 11, 2021, prior to the U.S. market opening. The company will conduct a conference call at 8:00 a.m. Eastern Time, accessible via phone and a live webcast on their website. Royalty Pharma is recognized as the largest buyer of biopharmaceutical royalties, collaborating with various institutions and companies to fund innovation in the biopharmaceutical sector. The firm holds royalties on over 45 commercial products, aiding in therapy development and commercialization.

The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved a third-quarter dividend of $0.17 per Class A ordinary share. This dividend will be paid on September 15, 2021, to shareholders on record by the close of business on August 20, 2021. Royalty Pharma is a leading buyer of biopharmaceutical royalties and funds innovation across the biopharmaceutical industry, holding royalties for over 45 commercial products, including well-known therapies like Imbruvica and Xtandi.